

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Application Number 20-323/S-021**

**ESTABLISHMENT EVALUATION REPORT**

NDA 20-323/S-021

Vivelle® (estradiol transdermal system) 0.0375, 0.05, 0.75, 0.1 mg/day

Novartis Pharmaceutical Corporation

**EER**

No changes have been made regarding establishments. No inspection is necessary.

**APPEARS THIS WAY  
ON ORIGINAL**